Christopher Van Dyck, MD

Christopher Van Dyck, MD
Geriatric Psychiatry, Memory Disorders & Cognitive Neurology
Accepting new patients? Yes
Referrals required? From patients or physicians
Patient type treated: Older Adult
Board Certified in Psychiatry

Christopher H. van Dyck, MD, is Professor of Psychiatry, Neurology, and Neuroscience; Director of the Alzheimer's Disease Research Unit; Director, Yale Alzheimer's Disease Research Center; Director, Division of Aging and Geriatric Psychiatry.

His research focuses on neuroimaging and therapeutic studies of Alzheimer’s disease (AD) and brain aging. His current imaging research utilizes positron emission tomography (PET) to study the beta-amyloid (Aβ) and tau proteins, as well as the synaptic targets SV2A and mGluR5. He and his team are examining the full spectrum of AD, including AD-dementia, the prodromal condition of amnestic Mild Cognitive Impairment (aMCI), and preclinical AD—in individuals at high familial and genetic risk. 

He also has extensive experience in the conduct and leadership of therapeutic trials in AD. Since 1991 he has led or participated in approximately 90 clinical trials for AD, including the prodromal or preclinical stages. He currently serves on the Steering and Executive Committees and Co-Chairs the Protocol Evaluation Committee of the Alzheimer’s Clinical Trials Consortium (ACTC). His research accomplishments have been recognized by receipt of the 1996 Junior Investigator Award of the American Association of Geriatric Psychiatry, the 2005 Compassion and Cure Award of the Alzheimer’s Association, and the 2017 Leader in Advancing Research Award of the Alzheimer’s Association.

Clinical Trials

New treatments for many conditions are tested in clinical trials, which ultimately bring lifesaving new drugs and devices to the patients who need them most. By participating in a clinical trial, you may get access to the most advanced treatments for your condition, and help determine their benefits for future patients.